Showing results (91-100 of 242) with videos related to
Sort By:
Pageof 25
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 17, 2024
Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM databaseKaushal Parikh, Anastasios Dimou, Konstantinos Leventakos, et al.Sensors (Basel, Switzerland)|November 9, 2019
Deep Learning on Multi Sensor Data for Counter UAV Applications-A Systematic ReviewStamatios Samaras, Eleni Diamantidou, Dimitrios Ataloglou, et al.JTO Clinical and Research Reports|May 8, 2025
Combination of Lurbinectedin and Osimertinib for Treatment of <i>EGFR</i>-Mutated Transformed SCLC: A Brief ReportAditi Singh, Arthi Sridhar, Aastha Poddar, et al.Journal of Microelectromechanical Systems : a Joint IEEE and ASME Publication on Microstructures, Microactuators, Microsensors, and Microsystems|October 4, 2024
Gold Nanorod-Embedded PDMS Micro-Pillar Array for Localized Photothermal StimulationNafis Mustakim, Luis F Rodriguez Vera, Jose Pacheco Pinto, et al.Clinical Breast Cancer|June 12, 2002
Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell linesFred R Hirsch, Barbara Helfrich, Wilbur A Franklin, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 3, 2007
Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trialGlen J Weiss, Everett E Vokes, Paul A Bunn, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 27, 2008
First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assayFred R Hirsch, Rafal Dziadziuszko, Marileila Varella-Garcia, et al.Molecular Cancer Therapeutics|June 2, 2007
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinomaBarbara A Frederick, Barbara A Helfrich, Christopher D Coldren, et al.Molecular Cancer Therapeutics|August 7, 2016
Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In VivoBarbara A Helfrich, Jihye Kim, Dexiang Gao, et al.Canadian Journal of Physiology and Pharmacology|May 25, 2002
Bradykinin-related compounds as new drugs for cancer and inflammationJohn M Stewart, Lajos Gera, Daniel C Chan, et al.Pageof 25